Apollomics Faces Nasdaq MVLS Deficiency, Reclaims $3.8M Rights to Vebreltinib
APLM•Apollomics received a Nasdaq notice for failing to maintain the $35 million minimum Market Value of Listed Securities after 30 consecutive days, triggering a compliance period that expires December 15, 2026. It also terminated its $3.8 million collaboration with Launxp, regaining global rights to vebreltinib outside Mainland China and Macau.
1. Nasdaq Deficiency Notice
Apollomics received a Nasdaq notice on June 18, 2026, for failure to maintain a $35 million minimum Market Value of Listed Securities after 30 consecutive days from May 6 to June 17, triggering a 180-day compliance window to restore MVLS or face delisting.
2. Termination and Dispute Process
Effective June 11, Apollomics terminated its collaboration with Launxp for nonpayment of the remaining $3.8 million upfront balance plus interest, initiating a 30-day negotiation followed by escalation to executive-level dispute resolution to recover funds and defend termination rights.
3. Vebreltinib Rights Reversion
With licenses to vebreltinib automatically reverting from Launxp, Apollomics now holds all development and commercialization rights for its c-Met inhibitor outside Mainland China and Macau, consolidating strategic control across the U.S., Europe and broader Asia-Pacific region.
